医学
多发性骨髓瘤
微小残留病
肿瘤科
干细胞
内科学
自体干细胞移植
残余物
临床试验
移植
文本挖掘
梅德林
外科
骨移植
生物信息学
作者
Si-Eun Oh,Sung‐Soo Park,Jung Yeon Lee,Jae‐Ho Yoon,Sung-Eun Lee,Hee‐Je Kim,Seung‐Hwan Shin,Young‐Woo Jeon,Seung‐Ah Yahng,Jin Hwa Jung,Ari Ahn,Myungshin Kim,Chang‐Ki Min
出处
期刊:Blood Research
[Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis]
日期:2025-10-23
卷期号:60 (1): 54-54
标识
DOI:10.1007/s44313-025-00101-6
摘要
PURPOSE: Tandem autologous stem cell transplantation (tASCT) is a viable option for high-risk multiple myeloma (MM) patients. Minimal residual disease (MRD), a real-time surrogate marker of disease burden, serves as a valuable measure of treatment response. This study evaluated the impact of tASCT on MRD dynamics in MM patients. METHODS: We analyzed data from a multicenter registry of 28 patients who underwent tASCT as frontline treatment between January 2019 and October 2024. Eligibility criteria included undergoing two ASCTs within one year, having MRD positivity before tASCT, and completing follow-up MRD assessment. Patients were stratified into two groups: extensive MRD clearance (≥ 50% reduction, n = 18) and modest MRD clearance (< 50% reduction, n = 10). RESULTS: Across the entire cohort, mean MRD decreased from 0.111% pre-tASCT to 0.056% post-tASCT. Three patients achieved MRD negativity, 20 had reductions without negativity, and five experienced increases. The extensive clearance group showed significant MRD reduction (0.152% to 0.017%) and longer progression-free survival (PFS: 37.7 vs. 16.3 months, p = 0.013) compared with the modest clearance group, in which MRD increased (0.175% to 0.830%). Overall survival did not differ significantly. CONCLUSIONS: tASCT provides clinical benefit for MRD-positive MM patients, particularly those achieving significant MRD reduction. These findings support tASCT as a feasible approach for MRD-positive patients following initial ASCT.
科研通智能强力驱动
Strongly Powered by AbleSci AI